TY - JOUR
T1 - Pharmacologic rescue of lethal seizures in mice deficient in succinate semialdehyde dehydrogenase
AU - Hogema, Boris M.
AU - Gupta, Maneesh
AU - Senephansiri, Henry
AU - Burlingame, Terry G.
AU - Taylor, Melissa
AU - Jakobs, Cornelis
AU - Schutgens, Ruud B.H.
AU - Froestl, Wolfgang
AU - Snead, O. Carter
AU - Diaz-Arrastia, Ramon
AU - Bottiglieri, Teodoro
AU - Grompe, Markus
AU - Gibson, K. Michael
N1 - Funding Information:
The authors acknowledge the contribution of M. Baetscher and J. Dekoning from the OHSU transgenic core facility in the development of the animal model, M. Al-Dhalimy and M. Noll for assistance with genotyping and animal studies, S. Akaboshi for assistance in characterization of murine seizures, H. Bartels for assistance with behavioral studies and amino acid analysis and C. Fernandez-Canon for providing the pgk-TK vector. The expert technical assistance of W. Guerand, V. Pereira and D. Schor in determination of metabolite levels in tissues and physiologic fluids is gratefully acknowledged. This work was supported in part by Research Grants No. 9813 from the Oregon Health Sciences Foundation (K.M.G.), #1-FY00-352 from the March of Dimes Birth Defects Foundation (K.M.G.), and NS 40270 from the National Institute of Neurological Disorders and Stroke, National Institutes of Health (K.M.G.). R.D.-A. was supported by P30 AG12300 and RO3 AG16450, from the National Institutes of Health.
PY - 2001
Y1 - 2001
N2 - Succinate semialdehyde dehydrogenase (ALDHSA1, encoding SSADH deficiency is a defect of 4-aminobutyric acid (GABA) degradation that manifests in humans as 4-hydroxybutyric (gamma-hydroxybutyric, GHB) aciduria. It is characterized by a non-specific neurological disorder including psychomotor retardation, language delay, seizures, hypotonia and ataxia. The current therapy, vigabatrin (VGB), is not uniformly successful. Here we report the development of Aldh5a1-deficient mice. At postnatal day 16-22 Aldh5a1-1- mice display ataxia and develop generalized seizures leading to rapid death. We observed increased amounts of GHB and total GABA in urine, brain and liver homogenates and detected significant gliosis in the hippocampus of Aldh5a1-1- mice. We found therapeutic intervention with phenobarbital or phenytoin ineffective, whereas intervention with vigabatrin or the GABAB receptor antagonist CGP 35348 (ref. 2) prevented tonic-clonic convulsions and significantly enhanced survival of the mutant mice. Because neurologic deterioration coincided with weaning, we hypothesized the presence of a protective compound in breast milk. Indeed treatment of mutant mice with the amino acid taurine rescued Aldh5a1-1- mice. These findings provide insight into pathomechanisms and may have therapeutic relevance for the human SSADH deficiency disease and GHB overdose and toxicity.
AB - Succinate semialdehyde dehydrogenase (ALDHSA1, encoding SSADH deficiency is a defect of 4-aminobutyric acid (GABA) degradation that manifests in humans as 4-hydroxybutyric (gamma-hydroxybutyric, GHB) aciduria. It is characterized by a non-specific neurological disorder including psychomotor retardation, language delay, seizures, hypotonia and ataxia. The current therapy, vigabatrin (VGB), is not uniformly successful. Here we report the development of Aldh5a1-deficient mice. At postnatal day 16-22 Aldh5a1-1- mice display ataxia and develop generalized seizures leading to rapid death. We observed increased amounts of GHB and total GABA in urine, brain and liver homogenates and detected significant gliosis in the hippocampus of Aldh5a1-1- mice. We found therapeutic intervention with phenobarbital or phenytoin ineffective, whereas intervention with vigabatrin or the GABAB receptor antagonist CGP 35348 (ref. 2) prevented tonic-clonic convulsions and significantly enhanced survival of the mutant mice. Because neurologic deterioration coincided with weaning, we hypothesized the presence of a protective compound in breast milk. Indeed treatment of mutant mice with the amino acid taurine rescued Aldh5a1-1- mice. These findings provide insight into pathomechanisms and may have therapeutic relevance for the human SSADH deficiency disease and GHB overdose and toxicity.
UR - http://www.scopus.com/inward/record.url?scp=0034795729&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034795729&partnerID=8YFLogxK
U2 - 10.1038/ng727
DO - 10.1038/ng727
M3 - Article
C2 - 11544478
AN - SCOPUS:0034795729
SN - 1061-4036
VL - 29
SP - 212
EP - 216
JO - Nature genetics
JF - Nature genetics
IS - 2
ER -